We are live on ! Find out more
VCYT icon

Veracyte

25.13 USD
+0.09
0.36%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
25.18
+0.05
0.2%
1 day
0.36%
5 days
4.84%
1 month
-43.89%
3 months
-39.87%
6 months
-44.39%
Year to date
-40.72%
1 year
-38.48%
5 years
-44.37%
10 years
228.5%
 

About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Employees: 755

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 18.8%
Neutral 62.5%
Negative 18.8%
Neutral
Seeking Alpha
4 days ago
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice Semiconductor and Cognex during the quarter. In addition to Modine Manufacturing, we ended our investment campaigns in Monolithic Power Systems and Tradeweb Markets.
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
Neutral
PRNewsWire
9 days ago
Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky
Needham reportedly cut its Veracyte price target by $23 per share after the Company's November 4, 2026 outlook reset on its Decipher Prostate test. An investigation into potential securities law violations is underway on behalf of VCYT shareholders who lost money.
Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky
Negative
Seeking Alpha
9 days ago
Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
Veracyte is rated Hold, as its valuation premium has vanished, but growth prospects have weakened, especially for Decipher prostate cancer testing. Decipher's test volume growth is slowing sharply, with management now planning for a 40% lower annual increase versus prior years. VCYT trades at 2.87x forward sales and 12.95x earnings, below sector medians, yet consensus expects a 19.38% EPS decline in 2027.
Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
Neutral
Seeking Alpha
11 days ago
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
Veracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good afternoon.
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
11 days ago
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)
Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)
Neutral
Business Wire
12 days ago
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
Positive
Zacks Investment Research
15 days ago
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
Neutral
Seeking Alpha
16 days ago
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript
Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel Lauren Timmins - Jefferies LLC, Research Division Mason Carrico - Stephens Inc., Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Michael Matson - Needham & Company, LLC, Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2026 Financial Results Conference Call.
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript
Neutral
PRNewsWire
16 days ago
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)
Veracyte stock fell more than 50% after the Company reported on November 4, 2026 that Decipher Prostate volume fell short of its expectations. Levi and Korsinsky investigates into potential securities law violations.
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)
Neutral
GlobeNewsWire
16 days ago
VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc.
VCYT's stock is down more than 50%; Ademi LLP is investigating Veracyte for potential securities fraud. CLICK HERE TO JOIN  MILWAUKEE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against Veracyte (Nasdaq: VCYT).
VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc.
Price charts implemented using Lightweight Charts™